EGFR gene amplification constitutes a diagnostic hallmark for glioblastoma, IDH-wildtype (GB, IDH-WT). Herein, we demonstrated that EGFR IHC is a highly specific and sensitive biomarker for identifying EGFR amplification and should be part of the neuropathologist's routine panel of antibodies.
Tauziède‐Espariat et al. (Wed,) studied this question.